je.st
news
Home
› Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70
Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70
2016-03-30 06:49:06| drugdiscoveryonline Home Page
Certara, the global biosimulation technology-enabled drug development company, recently announced that its regulatory and medical consultancy, Synchrogenix, has introduced an artificial intelligence (AI) -enabled solution to meet the data transparency requirements of the clinical and drug development market
Tags: policy
technology
unique
companies
Category:Biotechnology and Pharmaceuticals